Price movement over the last 24 hours
Accenture plc vs Tilray Brands Inc — how do they compare? Accenture plc trades at $138.43 (market cap $86.98B), while Tilray Brands Inc trades at $4.38 (market cap $532.10M). The key difference: Accenture plc is far larger — about 163.5× Tilray Brands Inc's market cap, and Accenture plc pays a 4.59% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| ACN | TLRY | |
|---|---|---|
Market Cap | $86.98B | $532.10M |
Sector | Technology | Health |
52-Week High | $303.33 | $21.00 |
52-Week Low | $124.41 | $4.31 |
Enterprise Value | $85.20B | $629.24M |
Dividend Yield | 4.59% | — |
Signals from Pluang's Aura AI — not financial advice
Accenture (ACN) trades at $136.96, down 0.28% on the day, with technical indicators showing a bearish bias despite recent earnings beats. The company reported strong revenue growth to $69.67B in 2025 with a net margin of 10.66%, supported by strategic AI partnerships announced in June 2026. Valuation ratios appear attractive with a P/E of 10.94 and EV/EBITDA of 6.65, while analyst consensus remains strongly bullish with a $193.92 price target.
The outlook is positive given consistent earnings outperformance, expanding AI-driven consulting partnerships, and solid cash flow generation. Key risks include competitive pressures in consulting services, execution challenges in integrating AI initiatives, and potential macroeconomic headwinds affecting client spending. The stock offers fundamental value with growth catalysts from digital transformation demand.
TLRY trades at $4.38, down 5.19% today, reflecting ongoing investor concerns about profitability despite revenue growth to $821 million in 2025. The stock shows bearish technical signals with key support at $4 and resistance at $5. Recent acquisitions and medical cannabis expansion provide growth avenues, but negative net income margins and cash flow challenges persist. Analyst consensus remains cautious with 65% hold ratings.
TLRY presents a high-risk opportunity with potential upside from strategic acquisitions and market expansion, but significant challenges include persistent losses, negative cash flow, and regulatory uncertainties. The stock's low P/S (0.54) and P/B (0.35) ratios suggest undervaluation, but profitability remains the critical hurdle for sustainable growth.
Trailing returns across standard periods
Latest headlines on both assets
Accenture PLC provides management and technology consulting services and solutions. The Company delivers a range of specialized capabilities and solutions to clients across all industries on a worldwide basis. Accenture operates a network of businesses provides consulting, technology, outsourcing, and alliances.
Read more on ACN →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →